Kane Biotech Announces Third Quarter 2024 Financial Results
Product sales for the three months ended September 30, 2024 was $597,677 compared to $3,631 in the three months ended September 30, 2023. During the third quarter, the Company recorded $594,705 from ...
NanoVibronix Faces Potential Delisting from Nasdaq Due to Non-Compliance
NanoVibronix, Inc. (NASDAQ: NAOV) received a notice on November 19, 2024, indicating that the company no longer met the $2.5 million stockholders’ equity requirement for continued listing on The ...
Ibj.com1d
GeniPhys builds momentum with wound care technology
After 10 long years, the company that has developed a collagen biomaterial to help heal tissue is readying itself for its ...
manilatimes4d
Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel
BioStem made the announcement on November 20, 2024. The company indicated that the acquisition of revyve TM Antimicrobial Wound Gel reflects BioStem's continued commitment to building a diverse ...
Morningstar3d
Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel
BioStem made the announcement on November 20, 2024. The company indicated that the acquisition of revyveTM Antimicrobial Wound Gel reflects BioStem’s continued commitment to building a diverse ...
Kane Biotech Inc.: Kane Biotech Announces Third Quarter 2024 Financial Results
Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) ("Kane Biotech", "Kane" or the "Company") today announces its third quarter 2024 financial results. Third ...
Business Insider5d
Sanara MedTech to Present at the Piper Sandler 36th Annual Healthcare Conference on December 4th
Sanara’s pipeline also contains potentially transformative product candidates for mitigation of opportunistic pathogens and biofilm, wound re-epithelialization and closure, necrotic tissue ...